SIGA Technologies Inc

$7.06 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About SIGA Technologies Inc

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on health security market. The Company’s lead product TPOXX is approved by the Unites States Food and Drug Administration (FDA) as a drug with an indication for treatment of smallpox. TPOXX is an oral formulation, which is also known as tecovirimat and ST-246. The Company is developing the intravenous (IV) formulation for patients who are unable to swallow oral capsules. It is also focused on developing post-exposure prophylaxis (PEP), liquid suspension pediatric formulation and ST-357. PEP regimens are designed to prevent infection in individuals who have known or exposure to an infectious agent but are not symptomatic. The Company is developing a second mechanism of action smallpox small molecule antiviral drug that has shown efficacy in animal models of the disease.

Stock Analysis

last close $7.06
1-mo return 7.1%
3-mo return 16.3%
avg daily vol. 200.02T
52-week high 7.85
52-week low 5.66
market cap. $534M
forward pe 9.5
annual div. -
roe 41.5%
ltg forecast -
dividend yield -
annual rev. $95M
inst own. 35.9%

Subscribe now for daily local and international financial news